GSK acquires BELLUS Health for $2 billion to boost cough drug pipeline.
GSK has agreed to acquire BELLUS Health, a late-stage biopharmaceutical company, for $2 billion, gaining access to camlipixant, a potential best-in-class treatment for refractory chronic cough. Camlipixant is a highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC. The acquisition is expected to be accretive to adjusted EPS from 2027 and has the potential to deliver significant sales through 2031 and beyond.